Additionally, Du's study demonstrated that elevated ALT, especially during ALT flare, was a strong predictor of HCC in CHB patients undergoing nucleoside analogue therapy, providing valuable monitoring insights for early detection of HCC. This evidence concerns the gene GPT and hepatocellular carcinoma.